Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 1
2022 6
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Transition practice for primary immunodeficiency diseases in Southeast Asia: a regional survey.
Chan CM, Abdul Latiff AH, Noh LM, Ismail IH, Abd Hamid IJ, Liew WK, Zhong Y, Suratannon N, Nantanee R, Santos-Ocampo FJ, Castor MAR, Nguyen-Ngoc-Quynh L, Van Nguyen AT, Thuc HT, Tuan NM, Muktiarti D, Amalia R, Chean S, Try L, Ali A. Chan CM, et al. Among authors: nantanee r. Front Immunol. 2023 Jul 13;14:1209315. doi: 10.3389/fimmu.2023.1209315. eCollection 2023. Front Immunol. 2023. PMID: 37529038 Free PMC article.
Phase II prefusion non-stabilised Covid-19 mRNA vaccine randomised study.
Puthanakit T, Prompetchara E, Gatechompol S, Ketloy C, Thitithanyanont A, Jongkaewwattana A, Buranapraditkun S, Ubolyam S, Kerr SJ, Sophonphan J, Apornpong T, Kittanamongkolchai W, Siwamogsatham S, Sriplienchan S, Patarakul K, Theerawit T, Promsena P, Nantanee R, Manomaisantiphap S, Chokyakorn S, Hong L, Samija M, Montefiori DC, Gao H, Eaton A, Wijagkanalan W, Alameh MG, Weissman D, Ruxrungtham K; ChulaVac001-Phase 2 study team. Puthanakit T, et al. Among authors: nantanee r. Sci Rep. 2024 Jan 29;14(1):2373. doi: 10.1038/s41598-023-49653-6. Sci Rep. 2024. PMID: 38287068 Free PMC article. Clinical Trial.
Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal route among adult who had received CoronaVac.
Nantanee R, Aikphaibul P, Jaru-Ampornpan P, Sodsai P, Himananto O, Theerawit T, Sophonphan J, Tovichayathamrong P, Manothummetha K, Laohasereekul T, Hiransuthikul N, Hirankarn N, Puthanakit T; Study Team. Nantanee R, et al. Vaccine. 2022 May 26;40(24):3320-3329. doi: 10.1016/j.vaccine.2022.04.067. Epub 2022 May 2. Vaccine. 2022. PMID: 35513961 Free PMC article.
A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines.
Nanthapisal S, Puthanakit T, Jaru-Ampornpan P, Nantanee R, Sodsai P, Himananto O, Sophonphan J, Suchartlikitwong P, Hiransuthikul N, Angkasekwinai P, Tangsathapornpong A, Hirankarn N; study team. Nanthapisal S, et al. Among authors: nantanee r. Vaccine. 2022 Apr 20;40(18):2551-2560. doi: 10.1016/j.vaccine.2022.03.036. Epub 2022 Mar 24. Vaccine. 2022. PMID: 35341647 Free PMC article. Clinical Trial.
Immunogenicity of a Fractional Dose of mRNA BNT162b2 COVID-19 Vaccine for Primary Series and Booster Vaccination among Healthy Adolescents.
Puthanakit T, Chantasrisawad N, Yoohat K, Nantanee R, Sophonphan J, Meepuksom T, Sodsai P, Phanthanawiboon S, Jantarabenjakul W, Hirankarn N, Kosalaraksa P. Puthanakit T, et al. Among authors: nantanee r. Vaccines (Basel). 2022 Sep 30;10(10):1646. doi: 10.3390/vaccines10101646. Vaccines (Basel). 2022. PMID: 36298510 Free PMC article.